Caspofungin (caspofungin): Reviews and patient testimonials

Caspofungin 50 mg powder for concentrate for solution for infusion

• Treatment of invasive candidiasis in adult or paediatric patients.

• Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

• Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.

Caspofungin 50 mg Powder for concentrate for solution for infusion

- Treatment of invasive candidiasis in adult or paediatric patients.

- Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

- Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropenic adult or paediatric patients.

Caspofungin 70 mg Powder for concentrate for solution for infusion

- Treatment of invasive candidiasis in adult or paediatric patients.

- Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

- Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropenic adult or paediatric patients.

Caspofungin 70 mg powder for concentrate for solution for infusion

Treatment of invasive candidiasis in adult or paediatric patients.

Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropenic adult or paediatric patients.